Eli Lilly Reports observational study Data for Olaparib in ALS

Eli Lilly today announced observational study results for Olaparib in patients with ALS. The study demonstrated that Olaparib reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of Olaparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Olaparib was consistent with previous observations, with no new safety signals identified.